These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
355 related articles for article (PubMed ID: 17020570)
21. [Indications for intravenous GPIIb/IIIa receptor inhibitors in acute coronary syndrome without prolonged ST syndrome]. Varenne O; Juliard JM; Benamer H; Steg PG; Vahanian A Arch Mal Coeur Vaiss; 2001 Nov; 94(11 Suppl):1251-8. PubMed ID: 11794966 [TBL] [Abstract][Full Text] [Related]
22. Glycoprotein IIb/IIIa inhibitors in patients with unstable angina/non-ST-segment elevation myocardial infarction: appropriate interpretation of the guidelines. Antman EM Am Heart J; 2003 Oct; 146(4 Suppl):S18-22. PubMed ID: 14564302 [TBL] [Abstract][Full Text] [Related]
23. [Glycoprotein IIB/IIIA receptor blockers as treatment of acute coronary syndromes and interventional cardiology]. Abramovitch N; Halon DA; Flugelman Y; Lewis BS Harefuah; 1998 Jul; 135(1-2):41-7. PubMed ID: 10909532 [No Abstract] [Full Text] [Related]
24. Facilitated angioplasty with combo therapy among patients with ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. De Luca G; Marino P Am J Emerg Med; 2009 Jul; 27(6):683-90. PubMed ID: 19751625 [TBL] [Abstract][Full Text] [Related]
25. The use of platelet glycoprotein IIb/IIIa receptor antagonists during the acute phase of myocardial infarction. van den Brand M; Ronner EF Semin Interv Cardiol; 1999 Jun; 4(2):85-8. PubMed ID: 10473877 [No Abstract] [Full Text] [Related]
26. [Safety and economic efficiency of platelet IIb/IIIa receptor blockers in acute coronary syndromes without ST-segment elevation]. Latour-Pérez J Rev Esp Cardiol; 2000 Aug; 53(8):1148-50. PubMed ID: 11032540 [No Abstract] [Full Text] [Related]
28. GPIIb-IIIa receptor inhibitors: what the interventional radiologist needs to know. Hofmann LV; Razavi M; Arepally A; Reginelli JP; Resar J; Geschwind JF; Corl F Cardiovasc Intervent Radiol; 2001; 24(6):361-7. PubMed ID: 11907740 [TBL] [Abstract][Full Text] [Related]
29. Patterns of upstream antiplatelet therapy use before primary percutaneous coronary intervention for acute ST-elevation myocardial infarction (from the CRUSADE National Quality Improvement Initiative). Alexander D; Mann N; Ou FS; Peterson ED; Ohman EM; Gibler WB; Roe MT Am J Cardiol; 2008 Nov; 102(10):1335-40. PubMed ID: 18993151 [TBL] [Abstract][Full Text] [Related]
30. The efficacy and safety of combination glycoprotein IIbIIIa inhibitors and reduced-dose thrombolytic therapy-facilitated percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis of randomized clinical trials. Sinno MC; Khanal S; Al-Mallah MH; Arida M; Weaver WD Am Heart J; 2007 Apr; 153(4):579-86. PubMed ID: 17383297 [TBL] [Abstract][Full Text] [Related]
31. Glycoprotein IIb/IIIa receptor antagonists: are we ignoring the evidence. Singh S; Gopal AK; Bahl VK Indian Heart J; 2005; 57(3):201-9. PubMed ID: 16196176 [No Abstract] [Full Text] [Related]
32. Glycoprotein IIb/IIIa antagonists in acute coronary syndromes: where are we now? Maree A; Fitzgerald DJ Semin Vasc Med; 2003 Nov; 3(4):385-90. PubMed ID: 15199445 [TBL] [Abstract][Full Text] [Related]
33. Landmarks: examining the foundation for GP IIb/IIIa inhibitors in PCI. J Invasive Cardiol; 2002 Dec; 14(12):776-9. PubMed ID: 12537005 [No Abstract] [Full Text] [Related]
34. [Acute coronary ischemic syndrome without ST elevation. Role of glycoprotein IIB/IIIA inhibitors and percutaneous coronary interventions]. Peña Duque MA Arch Cardiol Mex; 2006; 76 Suppl 2():S249-51. PubMed ID: 17017111 [TBL] [Abstract][Full Text] [Related]
35. [Acute coronary syndromes without ST-segment elevation. From randomized clinical trials, to consensus guidelines, to clinical practice in Italy: need to close the circle]. Savonitto S; Klugmann S Ital Heart J Suppl; 2004 Mar; 5(3):167-76. PubMed ID: 15116860 [TBL] [Abstract][Full Text] [Related]
37. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis. O'Donoghue M; Antman EM; Braunwald E; Murphy SA; Steg PG; Finkelstein A; Penny WF; Fridrich V; McCabe CH; Sabatine MS; Wiviott SD J Am Coll Cardiol; 2009 Aug; 54(8):678-85. PubMed ID: 19679245 [TBL] [Abstract][Full Text] [Related]
38. Role of enoxaparin in the invasive management of the ACS patient. Hermiller JB J Invasive Cardiol; 2004 Feb; 16(2):52-3. PubMed ID: 14760189 [No Abstract] [Full Text] [Related]
39. GP IIb-IIIa inhibitors administered upstream: evidence for improved outcomes with conventional and newer antithrombotic agents? Tricoci P; Newby LK Cardiol Rev; 2008; 16(2):89-94. PubMed ID: 18281911 [TBL] [Abstract][Full Text] [Related]
40. Proper use of glycoprotein IIb/IIIa inhibitors in patients with non-sT elevation acute coronary syndromes undergoing coronary angiography: frankly, my dear, I don't give a damn. Bovenzi F; De Luca L J Cardiovasc Med (Hagerstown); 2006 Mar; 7(3):166-8. PubMed ID: 16645380 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]